skip to Main Content

Meet DiagNovus from Health Innovators

The four teams that have just completed the first Health Innovators course have experienced great development. Here is how the team DiagNovus developed its idea in the course of the 13-week process.

Non-Prescription Test for Chlamydia

Jannik, Emil and Philip are studying Biology-Biotechnology at the University of Copenhagen. Together they make up the team DiagNovus, which is one of the teams that have participated in Health Innovators during the spring of 2017.

Easier to Test

DiagNovus has focussed on producing a non-prescription test for chlamydia. ’Chlamydia is an awkward and, at times, asymptomatic disease. Therefore, we need to make it easier to test for it’, Jannik said at the final pitch event.

Changed Technologies in the Process

The team originally intended the test to be similar to a home pregnancy test, but it was not as straightforward as that. Chlamydia can be present in relatively few cells in the body, so when a fairly small amount of urine hits the test stick it may not necessarily contain enough cell material to detect the disease. Therefore, the team had to switch to a different technology in the process. DiagNovus has now developed a new method, which of course we cannot reveal here, but which is able to detect even a small amount of chlamydia in the urine.

‘DiagNovus has learned what is possible with their solution, and changing technologies was an important step. Now they need to explore the technical challenges and not least the patent landscape, so they can find a niche where they have a commercial edge’, says Professor Claus Bøttcher Jørgensen, who has supervised the team.

Future Focus

DiagNovus is currently in the process of attracting funding for testing the method in the lab to prove its functionality. The team’s research has shown that supermarkets are interested in this type of test, so if they manage to ensure high sensitivity and produce a test at the same price level as home pregnancy tests they believe their idea holds great potential.

The activity is a part of  CHI-VEST, and is financed by: